{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Differentiation&page=5", "query": { "condition": "Differentiation", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 406, "total_pages": 41, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Differentiation&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Differentiation&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T20:07:15.725Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03870399", "title": "Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Tumors", "Progesterone Receptor Positive Tumor", "Estrogen Receptor Positive Tumor" ], "interventions": [ { "name": "Tamoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AC Camargo Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2019-03-13", "completion_date": "2023-05-13", "has_results": false, "last_update_posted_date": "2024-05-06", "last_synced_at": "2026-10-25T20:07:15.725Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03870399" }, { "nct_id": "NCT06458036", "title": "Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Differentiated Thyroid Cancer", "Pediatric Cancer", "Cancer", "Cancer, Thyroid" ], "interventions": [ { "name": "Selpercatinib Monotherapy", "type": "DRUG" }, { "name": "131I Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "2 Years to 25 Years" }, "enrollment_count": 13, "start_date": "2024-07-29", "completion_date": "2031-11-01", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-10-25T20:07:15.725Z", "location_count": 5, "location_summary": "San Francisco, California • Philadelphia, Pennsylvania • Memphis, Tennessee + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06458036" }, { "nct_id": "NCT07339085", "title": "Advanced Magnetic Resonance Imaging for the Identification of Recurrent Brain Tumors and Radiation Necrosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Malignant Brain Neoplasm", "Metastatic Malignant Neoplasm in the Brain" ], "interventions": [ { "name": "Advanced Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2025-08-28", "completion_date": "2030-07-30", "has_results": false, "last_update_posted_date": "2026-01-15", "last_synced_at": "2026-10-25T20:07:15.725Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07339085" }, { "nct_id": "NCT06843967", "title": "A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Well Differentiated Liposarcoma", "Dedifferentiated Liposarcoma", "Liposarcoma", "Myxoid Liposarcoma", "Round Cell Liposarcoma", "Myxoid Pleomorphic Liposarcoma", "Pleomorphic Liposarcoma", "Unresectable Liposarcoma", "Unresectable Dedifferentiated Liposarcoma" ], "interventions": [ { "name": "Mirdametinib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2025-02-19", "completion_date": "2028-08-19", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-25T20:07:15.725Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06843967" }, { "nct_id": "NCT06747949", "title": "A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sjögren's Syndrome" ], "interventions": [ { "name": "Dazodalibep", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 844, "start_date": "2025-02-25", "completion_date": "2029-12-11", "has_results": false, "last_update_posted_date": "2026-04-28", "last_synced_at": "2026-10-25T20:07:15.725Z", "location_count": 31, "location_summary": "Avondale, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 27 more", "locations": [ { "city": "Avondale", "state": "Arizona" }, { "city": "Flagstaff", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06747949" }, { "nct_id": "NCT00070174", "title": "Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "asparaginase", "type": "DRUG" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "gemtuzumab ozogamicin", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 350, "start_date": "2003-12", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2014-02-20", "last_synced_at": "2026-10-25T20:07:15.725Z", "location_count": 134, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 111 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00070174" }, { "nct_id": "NCT03841617", "title": "The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thyroid Cancer" ], "interventions": [ { "name": "Thyrogen", "type": "DRUG" }, { "name": "I-131", "type": "RADIATION" }, { "name": "I-124", "type": "RADIATION" }, { "name": "Thyroid hormone withdrawal", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 30, "start_date": "2019-07-29", "completion_date": "2035-11-01", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-25T20:07:15.725Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03841617" }, { "nct_id": "NCT00118248", "title": "Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Thyroid Cancer", "Stage IV Follicular Thyroid Cancer", "Stage IV Papillary Thyroid Cancer", "Thyroid Gland Medullary Carcinoma" ], "interventions": [ { "name": "tanespimycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2004-12", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2017-02-15", "last_synced_at": "2026-10-25T20:07:15.725Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00118248" }, { "nct_id": "NCT03065218", "title": "99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer (DTC) Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Thyroid Cancer" ], "interventions": [ { "name": "99mTc sestamibi", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medstar Health Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2016-10", "completion_date": "2021-02-15", "has_results": true, "last_update_posted_date": "2022-07-26", "last_synced_at": "2026-10-25T20:07:15.725Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03065218" }, { "nct_id": "NCT00268242", "title": "Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Mitoxantrone Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2006-01", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2018-02-22", "last_synced_at": "2026-10-25T20:07:15.725Z", "location_count": 2, "location_summary": "Durham, North Carolina • Cleveland, Ohio", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00268242" } ] }